Nearly 480 adults to join Alkermes’ late-stage narcolepsy studies Three 12-week placebo-controlled studies target narcolepsy types 1 and 2, with about 480 patients total and a long-term safety extension after completion.

#ALKS Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

www.stocktitan.net/news/ALKS/alkermes-annou...

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc Alkermes (Nasdaq: ALKS) agreed to increase its recommended offer to acquire Avadel (Nasdaq: AVDL) to up to $22.50 per share — consisting of $21.00 cash plus one non-transferable contingent value right (CVR) payable up to $1.50 if final FDA approval for LUMRYZ for idiopathic hypersomnia in adults is achieved by the end of 2028.The Increased Offer values Avadel at up to approximately $2.37 billion. The Amended Agreement was approved by both boards and the transaction remains expected to close in Q1 2026, subject to customary conditions and an extended End Date. J.P. Morgan provided fully committed financing for Alkermes.

#ALKS #AVDL Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

www.stocktitan.net/news/ALKS/alkermes-plc-a...

Alkermes Response to Avadel Announcement Alkermes (Nasdaq: ALKS) responded on November 14, 2025 to Avadel's announcement about a possible Lundbeck offer for Avadel. Alkermes said its board is considering options with advisors and reiterated contractual protections in the existing Transaction Agreement.Key contractual points: Avadel cannot terminate the agreement to accept a Company Superior Proposal unless its board, in good faith, determines doing so meets fiduciary duties and Avadel gives Alkermes at least five (5) Business Days written notice and engages in good‑faith discussions about amendments. Avadel also cannot change its board recommendation or sign with Lundbeck until those steps occur. Alkermes said a further announcement will follow as appropriate and will post this release on its website by 12:00 p.m. ET on November 17, 2025.

#ALKS Alkermes Response to Avadel Announcement

www.stocktitan.net/news/ALKS/alkermes-respo...

Alkermes plc Reports Third Quarter 2025 Financial Results —Third Quarter Revenues of $394.2 Million—. —GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49—. DUBLIN, Oct. 28, 2025/ PRNewswire/-- Alkermes plc today reported financial results for the third quarter of 2025..

#ALKS Alkermes plc Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/ALKS/alkermes-plc-r...

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 Alkermes (Nasdaq: ALKS) announced positive results from the Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1 (NT1) patients at World Sleep Congress 2025. The study demonstrated clinically meaningful and statistically significant improvements in wakefulness, cognition, and fatigue across all tested doses (4mg, 6mg, and 8mg).Key findings include: All dose groups achieved normative wakefulness with mean sleep latency of 24-28 minutes, significant improvements in the Epworth Sleepiness Scale, and over 40% of patients at higher doses achieved complete cataplexy reduction. The drug was generally well-tolerated with no serious adverse events reported.Based on these results, Alkermes plans to initiate a global phase 3 program in Q1 2026. Additional phase 2 studies (Vibrance-2 and Vibrance-3) are ongoing for narcolepsy type 2 and idiopathic hypersomnia.

#ALKS Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

www.stocktitan.net/news/ALKS/alkermes-prese...

Alkermes Reports Strong Q2 Earnings: All 3 Key Products Show Double-Digit Growth Just reported: See how Alkermes achieved $391M revenue with growth across VIVITROL, ARISTADA, and LYBALVI, plus breakthrough narcolepsy trial results. Get details.

#ALKS Alkermes plc Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/ALKS/alkermes-plc-r...

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 Alkermes (NASDAQ:ALKS) announced positive topline results from its Vibrance-1 Phase 2 study of alixorexton in patients with narcolepsy type 1 (NT1). The study met its primary endpoint, demonstrating statistically significant improvements in wakefulness across all tested doses (4mg, 6mg, and 8mg) compared to placebo.The once-daily oral treatment showed clinically meaningful improvements in multiple areas: normalized wakefulness (MWT), reduced excessive daytime sleepiness (ESS), and improved patient-reported outcomes related to disease severity, fatigue, and cognition. The drug was generally well-tolerated, with no serious adverse events reported. Over 95% of participants continued into the seven-week open-label extension.Based on these positive results, Alkermes plans to advance alixorexton to Phase 3 development for NT1. Detailed results will be presented at the World Sleep Congress in September 2025.

#ALKS Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

www.stocktitan.net/news/ALKS/alkermes-annou...

New Clinical Data: 4-Year Study Reveals LYBALVI Safety Profile in Schizophrenia and Bipolar Treatment Latest research unveils long-term safety outcomes for LYBALVI across multiple patient subgroups. New insights on lipid and glycemic profiles from 4-year study. See full data.

#ALKS Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

www.stocktitan.net/news/ALKS/alkermes-highl...

Breakthrough Sleep Disorder Treatment Advances: Phase 2 Trial Targets 40,000 Patient Market New orexin receptor agonist targets idiopathic hypersomnia in global Phase 2 study. Multi-dose trial launches across US, Europe & Australia. Full analysis inside.

#ALKS Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

www.stocktitan.net/news/ALKS/alkermes-annou...

Alkermes Smashes Expectations: $1B+ Product Sales Milestone, Achieves Debt-Free Status in 2024 Earnings Alkermes delivers strong 2024 performance with $372.1M net income, 18% product sales growth, and achieves debt-free status. 2025 guidance reflects continued growth focus.

#ALKS Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

www.stocktitan.net/news/ALKS/alkermes-plc-r...

#ALKS Alkermes to Participate in Upcoming Investor Conferences

www.stocktitan.net/news/ALKS/alkermes-to-pa...

Just In: ( NASDAQ: #ALKS ) Alkermes plc Reports Second Quarter 2024 Financial Results

#StockMarket #News

News; ( NASDAQ: #ALKS ) Expected US Company Earnings on Wednesday, July 24th, 2024

#StockMarket #News